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Low-density lipoprotein apheresis retards the progression of move a large amount of plasma lipid directly from pa-
hyperlipidemic overt diabetic nephropathy. tients in a short time. If hyperlipidemia played an impor-
Background. Hyperlipidemia has recently received atten- tant role in the progression of renal diseases, it shouldtion as being involved in the progression of diabetic nephropa-
be possible to improve renal injury by LDL-A. Somethy (DN). Low-density lipoprotein apheresis (LDL-A) can re-
successful clinical results were already reported for pri-move a large amount of plasma lipid directly from the patients
in a short time. mary nephrotic syndrome caused by focal glomeruloscle-
Methods. Fifteen type 2 diabetic patients with overt ne- rosis [4, 5]. LDL-A, however, has not yet been used in
phropathy received LDL-A in two different manners: short- patients with DN. In this study, we performed LDL-Aterm intensive therapy (SIT) for nine patients and long-term
in hyperlipidemic overt DN patients to evaluate the ef-intermittent therapy (LIT) for six patients.
fect of this therapy on the progression of DN.Results. The changes in the monthly decline rates of recipro-
cal serum creatinine (1/Cr) were 20.035 6 0.020 in the three-
month period before SIT, 0.047 6 0.041 during and until two
METHODSweeks after SIT, and 20.035 6 0.015 after a period of two
weeks from the therapy. The mean duration of LIT in six Patients
patients was 8.2 6 7.4 months, and the mean monthly decline
Fifteen type 2 diabetic patients (nine males and sixrates of 1/Cr significantly decreased during the period of LIT
as compared with the six-month period before the treatment. females, mean age 60.3 6 6.4) with nephropathy were
Conclusion. LDL-A can retard the progression of overt DN, enrolled in this study. Their mean creatinine clearance
especially when it is performed repeatedly for a long period was 35.6 6 19.2 ml/min, serum creatinine 2.1 6 1.4at two-week intervals.
mg/dl, and urinary protein excretion 6.8 6 2.9 g/day, and
their renal function was progressively declining. Their
mean serum cholesterol was 298.4 6 49.1 mg/dl, triglycer-The prime pathogenetic factor of diabetic nephropa-
ides 272.3 6 196.5 mg/dl, LDL 842.7 6 196.6 mg/dl, andthy (DN) is high blood glucose, and recent clinical and
very LDL (VLDL) 371.1 6 344.9 mg/dl, and their HbA1cepidemiological investigations have demonstrated that
was 7.9 6 1.3%. The mean arterial pressure (MAP) wasthe incidence of outbreak of DN was higher in poor-
99.4 6 6.5 mm Hg.control patients than in good-control patients with glyce-
All studies were conducted in accordance with themia [1]. In the progression of overt DN, in which protein-
principles set out in the Declaration of Helsinki, anduria has progressed to the nephrotic range, however, the
informed consent was obtained from all patients.adequacy of blood glucose control has only a limited
impact [2]. The fall of glomerular filtration rate in ne- Low-density lipoprotein apheresis
phrotic DN is usually rapid and appears to be linear with
The LDL-A system consists of polysulfone fibers (Sul-time. Therefore, the factors other than hyperglycemia
flux; Kaneka, Japan) as the plasma separator and a dex-have been suggested to contribute to such progression,
tran sulfate cellulose column (Liposorba15LA; Kaneka)and hyperlipidemia has recently received attention as
as the lipid absorber. One hundred to 150 ml per minuteone of the factors incriminated in this process [3].
of blood flow was circulated extracorporeally from theLow-density lipoprotein apheresis (LDL-A) can re-
femoral vein to the anticubital vein via the LDL-A sys-
tem. In a single LDL-A procedure, a total of 4000 ml of
Key words: diabetic nephropathy, hyperlipidemia, LDL apheresis. plasma was treated during two to three hours.
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therapy (SIT) and long-term intermittent therapy (LIT),
were instituted. In SIT, a total of six LDL-A procedures
were performed twice a week during three weeks, and
in LIT, LDL-A was performed once every two weeks
for as long a period as possible. SIT was conducted in the
first nine consecutive patients, and LIT was conducted in
the next six consecutive patients. There were no statisti-
cally significant differences between SIT and LIT pa-
tients in creatinine clearance (35.5 6 19.2 vs. 23.7 6 8.6
ml/min), urinary protein excretion (6.6 6 3.5 vs. 8.3 6
2.5 g/day), serum creatinine (2.4 6 1.4 vs. 2.4 6 0.5
mg/dl), serum total cholesterol (264.0 6 40.8 vs. 303.5 6
Fig. 1. Effects of short-term intensive therapy (SIT) of low-density53.3 mg/dl), serum triglycerides (264.6 6 268.3 vs.
lipoprotein apheresis on the decline rates of renal function in overt246.7 6 70.7 mg/dl), and serum VLDL (336.0 6 399.0 diabetic nephropathy. Improvement of monthly decline rates of recipro-
vs. 369.2 6 199.3 mg/dl). Serum LDL was significantly cal serum creatinine (1/Cr) were observed during SIT. These effects,
however, were only transient, and from two weeks after the last therapy,higher in LIT than SIT patients (1000.3 6 151.9 vs.
their renal function began to decline again at the same rates as before.767.1 6 172.0 mg/dl, P , 0.05).
Reduction rates of serum cholesterol, triglycerides,
LDL, and VLDL by single LDL-A were assessed in nine
Table 1. Effects of long-term intermittent therapy of LDL-apheresispatients. Serum LDL and VLDL levels before, immedi-
on the retardation of the renal function decline in overtately after, and two weeks after a single LDL-A were diabetic nephropathy
compared in seven patients. Serial changes in serum cre-
Decline rate (1/Cr/month)atinine, creatinine clearance, and urinary protein excre- Duration
Patient month Before Duringtion were measured during the study period in all pa-
1 22 20.032 20.010tients.
2 11 20.060 20.006Statistical analyses were performed using the paired
3 5 20.037 20.026
t-test and Student’s t-test. 4 5 20.108 20.046
5 4 20.037 20.001
6 2 20.034 20.015
Mean 8.267.4 20.05160.030 20.02260.015aRESULTS
P 5 0.022Changes in serum lipids concentrations by low-density
lipoprotein apheresis
Serum lipids concentrations were significantly de-
creased by single LDL-A, and the reduction rates of These effects, however, were only transient, and from
two weeks after the last therapy, their renal functionserum cholesterol, triglycerides, LDL, and VLDL were
58.6 6 7.3, 57.9 6 11.1, 73.4 6 14.9, and 75.8 6 16.7%, began to decline again at the same rates as before. The
changes in the monthly decline rates of reciprocal serumrespectively. Serum LDL levels before, immediately
after, and at two weeks after a single LDL-A were 677.9 6 creatinine (1/Cr) were 20.035 6 0.020 in the three-
month period before SIT, 0.047 6 0.041 during and until75.6 mg/dl, 168.3 6 40.2 mg/dl, and 615.3 6 38.9 mg/dl,
respectively, and serum VLDL levels at those times were two weeks after SIT, and 20.035 6 0.015 after the period
of two weeks from the therapy (Fig. 1).397.6 6 205.9 mg/dl, 165.3 6 129.9 mg/dl, and 489.1 6
192.1 mg/dl, respectively. Serum LDL and VLDL con-
Effects of long-term intermittent therapycentrations were significantly lower immediately after
than before a single LDL-A (P , 0.001); however, there Mean duration of LIT in six patients was 8.2 6 7.4
months. During the period of LIT, the mean monthlywas no significant difference between before and two-
week levels after a single LDL-A. decline rates of 1/Cr significantly decreased compared
with the six-month period before the therapy (Table 1).
Effects of short-term intensive therapy There were no significant changes in either their aver-
aged monthly measured HbA1c (8.1 6 1.5 vs. 8.0 6A patient whose serum creatinine was 6.1 mg/dl at the
start of SIT required hemodialysis because of overhydra- 1.6%) or MAP (100.2 6 5.6 vs. 106.8 6 10.2 mm Hg)
between a six-month period before LDL-A and duringtion two weeks after the beginning of SIT and dropped
out from the study. In the remaining eight patients, creat- the period of LDL-A. Figure 2 shows a typical case of
a 48-year-old woman, whose renal function decline wasinine clearance was increased in five. Urinary protein
excretion was reduced also in five, and serum creatinine effectively suppressed over a 22-month period by receiv-
ing LDL-A once every two weeks.was lowered in seven patients by two weeks after SIT.
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Fig. 2. A typical case of a 48-year-old woman
who received long-term intermittent therapy
(LIT). Her renal function decline was effec-
tively suppressed over a period of 22 months
by receiving low-density lipoprotein apheresis
once every two weeks.
DISCUSSION whether rapid lipid lowering by LDL-A is effective in
the retardation of progression of overt DN. In this study,Overt DN usually shows an irreversible linear decline
our preliminary results suggest that LDL-A could retardof the glomerular filtration rate. Recently, however,
the progression of overt DN, if it is performed repeatedlyblood pressure control, dietary protein restriction, and
at an interval of two weeks.angiotensin-converting enzyme inhibition have been es-
A rapid decrease of circulating lipids immediatelytablished as effective interventions to slow the progres-
after a single LDL-A procedure and lowering of time-sion of overt DN [6].
averaged concentrations of serum lipids by repeatingExperimental evidence suggests that hyperlipidemia
LDL-A might reduce the load of lipids on renal tissueparticipates in the progression of glomerular injury, and
and attenuate lipid-induced renal injury [14]. In additiona more rapid decline of renal function was observed in
to the previously mentioned mechanism, bradykinin,DN patients with hyperlipidemia than those without it
which increases during LDL-A [15], might alter renal[7, 8]. Lipid-lowering therapy using antilipemic agents
hemodynamics, contributing to improved renal function.such as HMG-CoA reductase inhibitors may have a ben-
Although a larger randomized controlled study is neededeficial effect on the retardation of progression of DN
to prove LDL-A as an effective therapy for DN, these[9–11]. However, this effect is controversial, and other
reports indicated no influence of antilipemic agents in data encourage further investigations.
the progression of DN [12].
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